Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Pfizer Inc.NYSE: PFE
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$220M, compared with $2.9B a year earlier. Trailing-twelve-month net income was $4.37B. Over 3 fiscal years it compounded at -37.2% a year.
Context
- Net income amounted to 12.4% of revenue in FY2025, down 0.2 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 18 analysts of $17.49B (+124.6%) for the fiscal year ending Dec 2026, a step up from the -3.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$220M-108.2% QoQ
- Last fiscal yearDec 2025
- $7.79B-3.3% YoY
- LTMJun 2026
- $4.37B-59.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -107.6% | +19.1% | +126.7 pp |
| 1 year | -3.3% | +124.6% | +127.8 pp |
| 3-year CAGR | -37.2% | +22.1% | +59.3 pp |
| 5-year CAGR | +11.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 7.79B USD
- Year-over-year change
- -3.3%
- 4-year CAGR
- -23.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.79B | -3.3% |
| FY2024 | 2024-12-31 | 8.05B | +270.5% |
| FY2023 | 2023-12-31 | 2.17B | -93.1% |
| FY2022 | 2022-12-31 | 31.4B | +39.8% |
| FY2021 | 2021-12-31 | 22.46B | — |
Net Income vs competitors
How PFE compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -59.4% is the 10th highest of 11, against a peer median of +4.5%.
- Net income amounts to 6.9% of revenue for PFE, versus a peer median of 17.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $26.71B USD | +93.6% | +49.0% | 33.5% | |
| LTM Sep 2026 | $16.1B USD | -35.9% | +14.3% | 16.2% | |
| LTM Jun 2026 | $12.76B USD | -6.4% | +32.5% | 22.9% | |
| LTM Sep 2026 | $11.82B USD | +15.4% | +59.9% | 19.0% | |
| LTM Jun 2026 | $9.27B USD | +83.1% | +3.6% | 18.9% | |
| LTM Jun 2026 | $6.32B USD | +66.4% | -29.1% | 9.8% | |
| LTM Jun 2026 | £5.62B GBP | +41.0% | +0.6% | 16.9% | |
| LTM Jun 2026 | $5.24B USD | -17.0% | +22.8% | 17.2% | |
| LTM Jun 2026 | $4.37B USD | -59.4% | -37.2% | 6.9% | |
| LTM Jun 2026 | €3.96B EUR | -46.8% | -11.2% | 8.1% | |
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| Peer median (excluding PFE) | — | +4.5% | +11.1% | 17.1% | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.46B | 31.4B | 2.17B | 8.05B | 7.79B |
| Depreciation & Amortization | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| Deferred Income Tax | (4.29B) | (3.76B) | (3.44B) | (2.1B) | (2.13B) |
| Stock-Based Compensation | 1.18B | 872M | 525M | 877M | 799M |
| Change in Working Capital | 12.8B | (4.46B) | (2.17B) | (3.07B) | (5.35B) |
| Accounts Receivables | (3.81B) | 261M | 347M | (109M) | (263M) |
| Inventory | (1.13B) | 592M | (1.17B) | (854M) | 561M |
| Accounts Payables | 1.24B | 1.19B | (300M) | (1.02B) | (469M) |
| Other Working Capital | 16.5B | (6.5B) | (1.05B) | (1.08B) | (5.18B) |
| Other Non-Cash Items | (4.76B) | 150M | 5.33B | 1.97B | 4.01B |
| Operating Cash Flow | 32.58B | 29.27B | 8.7B | 12.74B | 11.71B |
| Capital Expenditures | (2.71B) | (3.24B) | (3.91B) | (2.91B) | (2.63B) |
| Acquisitions (Net) | (12M) | (23B) | (43.43B) | 7.04B | (6.93B) |
| Purchases of Investments | (47.61B) | (38.78B) | (31.18B) | (10.31B) | (14.65B) |
| Sales of Investments | 28.1B | 45.46B | 46.42B | 8.83B | 22.69B |
| Other Investing Activities | (306M) | 3.77B | (180M) | 0 | 165M |
| Investing Cash Flow | (22.55B) | (15.78B) | (32.28B) | 2.65B | (1.35B) |
| Debt Repayment | (1.1B) | (3.52B) | 35.95B | (7.16B) | (74M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2B) | 0 | 0 | 0 |
| Dividends Paid | (8.73B) | (8.98B) | (9.25B) | (9.51B) | (9.77B) |
| Other Financing Activities | 16M | (335M) | (632M) | (469M) | (459M) |
| Financing Cash Flow | (9.82B) | (14.83B) | 26.07B | (17.14B) | (10.3B) |
| Effect of Forex Changes | (60M) | (165M) | (40M) | (66M) | 49M |
| Net Change in Cash | 158M | (1.52B) | 2.45B | (1.81B) | 99M |
| Free Cash Flow | 29.87B | 26.03B | 4.79B | 9.84B | 9.08B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.